BBT-877 Shows Strong Ability to Ease Lung Fibrosis, Early Study Shows

BBT-877 Shows Strong Ability to Ease Lung Fibrosis, Early Study Shows

The idiopathic pulmonary fibrosis (IPF) treatment candidate BBT-877 eased lung fibrosis (scarring) in a mouse model, according to South Korea-based Bridge Biotherapeutics. The company believes that BBT-877 may become the “best-in-class” medication for IPF. Data from a preclinical study on BBT-877 was presented at the 2nd Annual IPF…

Treatment with Plant Pigment Quercetin Reduces Lung Fibrosis in Mouse Model, Study Reports

A plant-based medicine called quercetin reversed pulmonary fibrosis in a mouse model likely by reducing the burden of growth-arrested and fibrosis-promoting cells, called senescent cells, in the animals’ lungs, researchers report. Findings were published in the study, “Quercetin enhances ligand-induced apoptosis in senescent IPF fibroblasts and reduces lung…

Repeated Lung Cancer Surgery in IPF Patients May Worsen Outcomes

Surgery for lung cancer should be carefully considered in patients who also have idiopathic pulmonary fibrosis (IPF), because it is associated with poor outcomes, a study shows. The study, “Survival after repeated surgery for lung cancer with idiopathic pulmonary fibrosis: a retrospective study,” was published in the journal…

Extracellular Vesicles Likely Play Role in IPF Development, Study Reports

Tiny extracellular vesicles that carry information from one cell to another may contribute to the development of idiopathic pulmonary fibrosis (IPF) by carrying molecules involved in the disease, a study has found. The study, “Increased Extracellular Vesicles Mediate WNT-5A Signaling in Idiopathic Pulmonary Fibrosis,” was published in the…

Getting the Specialized Medical Help We Need

Most of us receive our medical care from our primary care doctor or a local pulmonologist. However helpful they may be, they don’t know everything about the rare disease that we have. Four years ago, the first pulmonologist I saw told me I had a few months to…